- Home
- IMCR vs EXPI Comparison
IMCR vs EXPI Comparison
Compare IMCR & EXPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- EXPI
- Stock Information
- Founded
- IMCR 2008
- EXPI 2008
- Country
- IMCR United Kingdom
- EXPI United States
- Employees
- IMCR N/A
- EXPI N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- EXPI Real Estate
- Sector
- IMCR Health Care
- EXPI Finance
- Exchange
- IMCR Nasdaq
- EXPI Nasdaq
- Market Cap
- IMCR 1.7B
- EXPI 1.8B
- IPO Year
- IMCR 2021
- EXPI N/A
- Fundamental
- Price
- IMCR $33.50
- EXPI $11.27
- Analyst Decision
- IMCR Buy
- EXPI Strong Buy
- Analyst Count
- IMCR 9
- EXPI 1
- Target Price
- IMCR $62.38
- EXPI $12.00
- AVG Volume (30 Days)
- IMCR 350.0K
- EXPI 974.5K
- Earning Date
- IMCR 11-06-2025
- EXPI 11-06-2025
- Dividend Yield
- IMCR N/A
- EXPI 1.77%
- EPS Growth
- IMCR N/A
- EXPI N/A
- EPS
- IMCR N/A
- EXPI N/A
- Revenue
- IMCR $356,145,000.00
- EXPI $4,593,157,000.00
- Revenue This Year
- IMCR $29.99
- EXPI $3.60
- Revenue Next Year
- IMCR $8.85
- EXPI $4.71
- P/E Ratio
- IMCR N/A
- EXPI N/A
- Revenue Growth
- IMCR 26.78
- EXPI 3.62
- 52 Week Low
- IMCR $23.15
- EXPI $6.90
- 52 Week High
- IMCR $39.33
- EXPI $15.22
- Technical
- Relative Strength Index (RSI)
- IMCR 49.73
- EXPI 57.89
- Support Level
- IMCR $31.36
- EXPI $10.64
- Resistance Level
- IMCR $34.18
- EXPI $11.56
- Average True Range (ATR)
- IMCR 1.38
- EXPI 0.30
- MACD
- IMCR -0.00
- EXPI 0.06
- Stochastic Oscillator
- IMCR 60.51
- EXPI 74.31
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About EXPI eXp World Holdings Inc.
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services. The company mainly operates in the United States and Canada, and it also has operations in the United Kingdom, Australia, South Africa, France, India, Portugal, and Mexico, among others.